Akebia Therapeutics | AKBA - الأصول





الأصول تغيير تاريخ
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Ardelyx USD 501.6M 15.43M 2025-12
Astellas Pharma JPY 3.6T 153.62B 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bayer EUR 104.54B 331M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Celltrion KRW 21.08T 530.63B 2025-09
Cspc Pharmaceutical CNY 46B 1.61B 2025-06
Deva Holding AS TRY 12.93B 1.83B 2023-09
Dianthus Therapeutics USD 530.92M 46.52M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Fresenius Medical Care EUR 31B 115.33M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
J&J USD 199.21B 6.39B 2025-12
Kangmei Pharma CNY 13.68B 38.19M 2025-09
Karyopharm Therapeutics USD 96.23M 8.65M 2025-09
Knight Therapeutics CAD 1.05B 2.28M 2025-12
Laboratorios Farma EUR 799.88M 99.95M 2023-12
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
Malin Corporation EUR 198.5M 70.1M 2024-12
Medical Developments International AUD 63.57M 2.83M 2025-12
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Neuren Pharmaceuticals AUD 342.86M 11.61M 2025-12
Organigram Holdings CAD 530.67M 31.54M 2025-12
Ovoca Bio EUR 11.41M 3.36M 2022-06
Pharma Mar EUR 395.08M 53.42M 2025-12
Prothena USD 326.8M 25.82M 2025-12
PTC Therapeutics USD 2.9B 255.07M 2025-12
Qiagen NV USD 6.3B 257.54M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Sartorius EUR 9.61B 413.4M 2025-09
Sino Biopharmaceutical CNY 74.89B 9.49B 2025-06
Tectonic Therapeutic USD 261.04M 15.96M 2025-12
Tilray USD 2.1B 15.95M 2025-09
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Zealand Pharma A/S 15.95B 848.45M 2025-12
Zz Pientze Pharmaceu CNY 17.48B 1.23B 2025-09